At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AKTX Akari Therapeutics PLC
Market Closed 08-14 16:00:00 EDT
7.54
+0.54
+7.71%
盘后7.69
+0.15+1.99%
19:34 EDT
High7.99Low6.51Vol164.32K
Open7.01D1 Closing7.00Amplitude21.14%
Mkt Cap14.68MTradable Cap5.24MTotal Shares1.95M
T/O1.17MT/O Rate23.66%Tradable Shares694.50K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
MT Newswires Live  ·  08-14 23:08
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101
Reuters  ·  08-14 05:33
UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101
Akari Therapeutics PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14 04:50
Akari Therapeutics PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of Aktx-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
THOMSON REUTERS  ·  08-14 04:15
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of Aktx-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Dow Jones  ·  08-14 04:15
Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Akari Net Loss Widens to $4.81 Million in Q2 FY26; Operating Loss Rises to $4.6 Million
Reuters  ·  08-14 04:04
Akari Net Loss Widens to $4.81 Million in Q2 FY26; Operating Loss Rises to $4.6 Million
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires Live  ·  08-11
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
MT Newswires Live  ·  08-10
European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
Akari Therapeutics PLC Expected to Post a Loss of $1.40 a Share - Earnings Preview
Reuters  ·  08-08
Akari Therapeutics PLC Expected to Post a Loss of $1.40 a Share - Earnings Preview
Akari Therapeutics Enters Research Collaboration with WhiteHawk Therapeutics on Dual-Payload ADCs
Reuters  ·  08-04
Akari Therapeutics Enters Research Collaboration with WhiteHawk Therapeutics on Dual-Payload ADCs
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
MT Newswires Live  ·  08-03
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European Equities Traded in the US as American Depositary Receipts Track Sharply Higher in Thursday Trading
MT Newswires Live  ·  07-30
European Equities Traded in the US as American Depositary Receipts Track Sharply Higher in Thursday Trading
European Equities Traded in US as ADRs Ease in Wednesday Trading
MT Newswires Live  ·  07-29
European Equities Traded in US as ADRs Ease in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
MT Newswires Live  ·  07-27
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
MT Newswires Live  ·  07-22
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Akari Therapeutics Enters Strategic ADC Payload Research Collaboration with Whitehawk Therapeutics
Reuters  ·  07-22
Akari Therapeutics Enters Strategic ADC Payload Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics Enters Preclinical ADC Research Collaboration with Whitehawk Therapeutics
Reuters  ·  07-21
Akari Therapeutics Enters Preclinical ADC Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics - Collaboration to Commence Immediately with Interim Data Updates Anticipated
THOMSON REUTERS  ·  07-21
Akari Therapeutics - Collaboration to Commence Immediately with Interim Data Updates Anticipated
Akari Therapeutics - Co and Whitehawk to Conduct Preclinical Studies of Ph1 Payload with Top1i ADC Platform
THOMSON REUTERS  ·  07-21
Akari Therapeutics - Co and Whitehawk to Conduct Preclinical Studies of Ph1 Payload with Top1i ADC Platform
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
THOMSON REUTERS  ·  07-21
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Introduction

Company Name.
Akari Therapeutics PLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Issue price:
--